Vaxil reverses onto Tel Aviv stock exchange
This article was originally published in Scrip
Israeli firm Vaxil BioTherapeutics has made its debut on the Israeli stock market having completed a reverse merger with Sheldonco, a 'shell' company traded on the Tel Aviv Stock Exchange. Vaxil will be fully acquired by Sheldonco with Vaxil shareholders receiving 56% of that company's share capital and increasing their holding up to 74% subject to milestone achievements.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.